Image source: Shutterstock
Highlights
- AVITA Medical is an ASX-listed regenerative medical company
- In 1QFY24, revenue of AVH jumped 5.3% YoY to USD 11.1 million
- Perry (Michael) has the highest stake in the company with the shareholding of ~0.93%
AVITA Medical, Inc. (ASX: AVH) is a regenerative medicine firm, dedicated to transforming wound care and skin restoration through cutting-edge devices. The company's portfolio features the RECELL® System, FDA-approved for treating thermal burns, full-thickness skin defects, and repigmenting stable depigmented vitiligo lesions. Additionally, AVITA holds exclusive rights to market, sell, and distribute PermeaDerm®, a biosynthetic wound matrix, across the United States.
In the first quarter of the financial year 2024 (1QFY24), the company recorded 5.3% YoY increase in its revenue to USD 11.1 million, 39.6% YoY fall in cash and cash equivalents to USD 16.9 million and increase in gross profit margin to 86.4% from 84.2% in 1QFY23. The period saw net loss of USD 18.7 million.
Top 3 shareholders of AVH
The top 3 shareholders of AVH have around 1.11% of the shareholding. Perry (Michael) and Panaccio (Louis James) have maximum stakes in the company with a shareholding of ~0.93% and ~0.15%, respectively.
Recent business update
Through an ASX update dated 11 July 2024, the company notified that it would release its second quarter 2024 financial results on 8 August 2024, following the closure of the US financial markets.
Outlook
In 2QFY24, the company expects to achieve commercial revenue of USD 14.3-15.3 million and in FY24, commercial revenue is expected to be within the lower range of USD 78.5-84.5 million.
The company targets cashflow break even and GAAP profitability before the third quarter of 2025.
In 2024, the focus is on sales execution, advancement of RECELL and international and product portfolio expansion.
Share performance of AVH
AVH shares closed 5.86% higher at AUD 3.070 apiece on 17 July 2024. In the last one year, AVH’s share price has dropped by almost 48.23% and in the past one month, it has increased by 21.83%.
52-week high of AVH is AUD 6.27, recorded on 31 July 2023, and the 52-week low is AUD 2.34, recorded on 4 July 2024.

AVH Daily Technical Chart, Source: REFINITIV
Note 1: Past performance is neither an Indicator nor a guarantee of future performance.
Note 2: The reference date for all price data, and currency, is 17 July 2024. The reference data in this report has been partly sourced from REFINITIV.
Disclaimer:
This article (“Article”) has been prepared by Kalkine Pty Limited (ABN 34 154 808 312) (Australian financial services licence number 425376) (“Kalkine”) and its related bodies corporate who are authorised to provide general financial product advice. Kalkine.com.au and its associated pages are published by Kalkine.
Any information/advice provided in this article is general in nature and does not take into account your objectives, financial situation or needs. You should therefore consider whether the information is appropriate for your objectives, financial situation and needs before acting upon it.
There may be a Product Disclosure Statement, Information Memorandum or other offer document (“Offer Document”) for the securities or other financial products referred to in Kalkine articles. You should obtain a copy of the Offer Document and consider it before making any decision about whether to acquire the security or financial product.
Kalkine strongly recommends that you seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) before acting on any advice/information in this Article or on the Kalkine website. Not all investments are appropriate for all people.
The information in this Article and on Kalkine website has been prepared from a wide variety of sources, which Kalkine, to the best of its knowledge and belief, considers accurate. Kalkine has made every effort to ensure the reliability of the information contained in its articles (including this Article), newsletters and websites. All information represents our views at the date of publication and may change without notice.
The information in this Article does not constitute an offer to sell securities or other financial products or a solicitation of an offer to buy securities or other financial products.
Kalkine does not issue, sell or deal in any financial products.
This Article may contain information on past performance of particular investments. Please note past performance is neither an indicator nor a guarantee of future performance.
To the extent permitted by law, and excluding any dishonesty or gross negligence by Kalkine, Kalkine disclaims and excludes all liability for any direct, indirect, implied, punitive, special, incidental or other consequential loss or damage arising from the use of or reliance on this Article, the Kalkine website and any information published on the Kalkine website without any warranties or representations by Kalkine to you. To the extent the law prohibits or limits this exclusion, Kalkine limits its liability to the resupply of services.
Please also read our Terms & Conditions and Financial Services Guide for further information.
Employees and/or associates of Kalkine and its related entities may hold interests in the securities or other financial products covered in this Article or on the Kalkine website. Any such employees and associates are required to comply with certain safeguards, procedures and disclosures as required by law.
Some of the images/music that may be used in the Article are copyright to their respective owner(s). Kalkine does not claim ownership of any of the pictures displayed/music used in the Article unless stated otherwise. The images/music that may be used in the Article are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated or was found to be necessary.
Kalkine Media Pty Ltd, an affiliate of Kalkine Pty Ltd, may have received, or be entitled to receive, financial consideration in connection with providing information about certain entity(s) covered on its website.
Copyright 2026 Krish Capital Pty. Ltd. (ABN 61629651510). All Rights Reserved. No part of this Article, or its content, may be reproduced in any form without our prior consent.